Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 166

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Targeting VDAC-bound hexokinase II: a promising approach for concomitant anti-cancer therapy

Krasnov, George S, Dmitriev, Alexey A, Lakunina, Valentina A, Kirpiy, Alexander A, Kudryavtseva, Anna V·2013·Expert Opinion on Therapeutic Targets

Abstract

INTRODUCTION: Enhancement of glucose metabolism and repression of oxidative phosphorylation followed by the Warburg effect is the common hallmark of cancer cells. Hexokinase II (HKII) plays a dual role - first, HKII up-regulation results in increased glycolysis rates. Second, association of VDAC and HKII contributes to inhibition of apoptosis through repression of the formation of mitochondrial permeability transition pores. AREAS COVERED: In this review, the role of HKII in evasion of apoptosis, aspects of HKII expression regulation, novel approaches targeting HKII and VDAC-HKII complexes and their application areas are discussed. EXPERT OPINION: The dual role of HKII in cancer cells makes it an attractive target for anti-cancer therapy. Several agents, either synthetic or plant-derived, that target hexokinase and induce VDAC-HK complex dissociation have been identified to date. Targeting hexokinase, HK-VDAC complexes as well as other glycolytic proteins not only improves the efficacy of commonly used drugs. The most prominent benefit of this approach is the ability to overcome drug resistance, for example, to cisplatin or sorafenib. In some cases, it could create an insurmountable challenge for selection of appropriate therapy. Future studies and trials should address the issue of how to transfer these approaches into clinical practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1517/14728222.2013.833607

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 166

Metadata

Authors
Krasnov, G. S., Dmitriev, A. A., Lakunina, V. A., Kirpiy, A. A., & Kudryavtseva, A. V.
Venue
Expert Opinion on Therapeutic Targets
Published
2013-08-28
Volume
17
Issue
10
Pages
1221-1233
ISSN
  • 1472-8222 (ISSN-L)
  • 1744-7631
OpenAlex
W2067005837
Cited by
166
References
11
FWCI
2.90
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting VDAC-bound hexokinase II: a promising approach for concomitant anti-cancer therapy. https://app.cochat.ai/papers/10.1517/14728222.2013.833607
The paper
Krasnov, G. S., Dmitriev, A. A., Lakunina, V. A., Kirpiy, A. A., & Kudryavtseva, A. V. (2013). Targeting VDAC-bound hexokinase II: a promising approach for concomitant anti-cancer therapy. Expert Opinion on Therapeutic Targets. https://doi.org/10.1517/14728222.2013.833607

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.